ribB

Abstract: The invention provides ribB polypeptides and polynucleotides encoding ribB polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ribB polypeptides to screen for antibacterial compounds.

Description: ribB RELATED APPLICATIONS This application claims benefit of US Patent Application Number 08/977,866 filed, November 25, 1997 FIELD OF THE INVENTION This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their vanants, agonists -and antagonists, and their uses In particular, the invention relates to novel polynucleotides and polypeptides of the nboflavin synth-ase (α-subunit) family, hereinafter referred to as "nbB" BACKGROUND OF THE INVENTION It is particularly preferred to employ Staphylococcal genes and gene products as targets for the development of antibiotics The Staphylococci make up a medically important genera of microbes They -are known to produce two types of disease, invasive and toxigemc Involve infections are charactenzed generally by abscess formation effecting both skin surfaces and deep tissues S αureus is the second leading cause of bacteremia in cancer patients Osteomyelitis, septic arthritis, septic thrombophlebitis and acute bactenal endocarditis are also relatively common There are at least three clinical conditions resulting from the toxigemc properties of Staphylococci The manifestation of these diseases result from the actions of exotoxins .as opposed to tissue invasion and bacteremia These conditions include Staphylococcal food poisoning, scalded skin syndrome -and toxic shock syndrome The frequency of Stαphylococcus αureus infections has nsen dramatically in the past few decades This has been attnbuted to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems It is no longer uncommon to isolate Stαphylococcus αureus strains which are resistant to some or all of the standard antibiotics This phenomenon has created a demand for both new anti-microbi-al agents, vaccines, and diagnostic tests for this organism Clearly, there exists a need for factors, such as the nbB embodiments of the invention, that have a present benefit of being useful to screen compounds for antibiotic activity Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease There is also a need for identification and charactenzation of such factors and their antagonists and agonists to find ways to prevent, ameliorate or correct such infection, dysfunction .and disease Certain of the polypeptides of the invention possess amino acid sequence homology to a known Actmobacilluspleuropneumomae nbB protein See Swiss Prot Accession No P50854, GenBank Accession No U27202 Also see Perkins, JB et al In Bacillus btύis and Other Gram-Positive Bacteria Eds Sonenshein, AL, Hoch, JA and Losick, R 1993 American Society for Microbiology Riboflavin (vitamin B2) is a member of the B complex of vitamins which function as coenzymes in metabolic reactions Riboflavin has two coenzyme forms, flavin mononucleotide (FMN) and flavm adenrne dmucleotide (FAD) which act m oxidation-reduction reactions such as the cytochrome system of electron transport and the oxidative degradation of pyruvate, fatty acids and ammo acids The first committed step in the biosynthesis of riboflavin is the opening of the lmidazole ring of GTP In the presence of 3 H2O and Mg ++ , the C-8 of GTP is released as formate accompanied by the release of pyrophosphate by the action of GTP cyclohyrolase II (GCH2, EC 3 5 4 25) This enzyme function is encoded by ribA in bacteria and nbl in yeast species Through a series of steps, involving 3,4-dιhydroxy-2-butanone 4 phosphate synthase (ribA), 6 7-dιmethyl-8-πbιt\llumazιne synthase (ribH), riboflavin synthase (ribB), pyπmidine deaminase and pyπmidine reductase (ribG) enzymes encoded by genes within the riboflavin biosynthesis operon. riboflavin is formed Because the genes required for riboflavin biosynthesis are present in many pathogenic microorganisms, and smce riboflavin biosynthesis has shown to be required for virulence in the swine pathogen Actmobacillus pleuropneumoniae (Fuller, TE, et al (1996) A riboflavin auxotroph of Actmobacillus pleuropneumoniae is attenuated in swme Infect Immun 64 4659-4664), these gen e products represent broad spectrum antibacterial as well as antifungal targets SUMMARY OF THE INVENTION It is an object of the invention to provide polypeptides that have been identified as novel nbB polypeptides by homology between the .amino acid sequence set out in Table 1 [SEQ ID NO 2 or 4] and a known amino acid sequence or sequences of other proteins such as Actmobacillus pleuropneumoniae nbB protein It is a further object of the invention to provide polynucleotides that encode nbB polypeptides, particularly polynucleotides that encode the polypeptide herein designated nbB In a particularly prefened embodiment of the invention the polynucleotide compnses a region encoding nbB polypeptides compnsing a sequence set out m Table 1 [SEQ ID NO 1 or 3] which includes a full length gene, or a variant thereof In another particularly preferred embodiment of the invention there is a novel nbB protem from Staphylococcus aureus comprising the amino acid sequence of Table 1 [SEQ ID NO 2 or 4], or a variant thereof A further aspect of the invention there .are provided isolated nucleic acid molecules encoding nbB, particularly Staphylococcus aureus nbB, including mRNAs, cDNAs, genomic DNAs Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful vanants thereof, and compositions compnsing the same In accordance with another aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization Among the particularly prefened embodiments of the invention are naturally occurring allelic vanants of nbB and polypeptides encoded thereby Another aspect of the invention there are provided novel polypeptides of Staphylococcus aureus refeπed to herein a nbB as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful vanants thereof, and compositions compnsing the same Among the particularly prefened embodiments of the invention are vanants of nbB polypeptide encoded by naturally occurring alleles of the nbB gene In a prefened embodiment of the invention there are provided methods for producing the aforementioned nbB polypeptides In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides, useful as antibacterial agents, including, for example, antibodies In accordance with certain prefened embodiments of the invention, there .are provided products, compositions and methods for .assessing nbB expression, treating disease, assaying genetic vanation, and administering a nbB polypeptide or polynucleotide to an organism to raise an lmmunological response against a bactena, especially a Stαphylococcus αureus bacteπa In accordance with certain prefened embodiments of this .and other .aspects of the invention there are provided polynucleotides that hybndize to nbB polynucleotide sequences, p.aιtιcularly under stringent conditions In certain prefened embodiments of the invention there are provided antibodies against nbB polypeptides In other embodiments of the invention there are provided methods for identifying compounds which bind to or otherwise interact with .and inhibit or activate an activity of a polypeptide or polynucleotide of the invention compnsing contacting a polypeptide or polynucleotide of the invention with a compound to be screened under conditions to permit binding to or other mteraction between the compound and the polypeptide or polynucleotide to assess the bmding to or other mteraction with the compound, such binding or interaction being associated with a second component capable of providing a detectable signal in response to the bmding or mteraction of the polypeptide or polynucleotide with the compound, and determinmg whether the compound bmds to or otherwise interacts with .and activates or inhibits .an activity of the polypeptide or polynucleotide by detectmg the presence or absence of a signal generated from the binding or mteraction of the compound with the polypeptide or polynucleotide In accordance with yet .another aspect of the invention, there are provided nbB agonists and antagonists, preferably bactenostatic or bactenocidal agonists and antagonists In a further aspect of the mvention there are provided compositions compnsmg a nbB polynucleotide or a nbB polypeptide for administration to a cell or to a multicellular organism Vanous changes and modifications within the spmt .and scope of the disclosed mvention will become readily apparent to those skilled m the art from reading the following descnptions and from reading the other parts of the present disclosure DESCRIPTION OF THE INVENTION The mvention relates to novel nbB polypeptides and polynucleotides as descnbed m greater detail below In particular, the mvention relates to polypeptides and polynucleotides of a novel nbB of Staphylococcus aureus, which is related by ammo acid sequence homology to Actmobacillus pleuropneumoniae nbB polypeptide The mvention relates especially to nbB having the nucleotide and .amino acid sequences set out m Table 1 as SEQ ID NO 1 and SEQ ID NO 2 respectively TABLE 1 ribB Polynucleotide and Polypeptide Sequences (A) Sequences from Staphylococcus aureus nbB polynucleotide sequence [SEQ ID NO 1] 5 ' - ATGTTTACTGGCATCGTTGAAGAAATAGGTGTCGTTAAAAGTGTTCAAATTCGTCAATCAGTCAGGACG ATTGAAATCGAAGCACATAAGATTACGGCAGATATGCATATTGGTGATTCCATCAGTGTTAATGGTGCA TGTTTAACAGTGATTGATTTTGATCAGACATCTTTTACTGTTCAAGTAATTAAAAGCACTGAAAATAAA ACCTATTTAGCAGATGTTAAGCGACAATCAGAAGTAAATTTAGAGCGTGCCATGAGTGGTAACGGTAGG TTTGGTGGACATTTTGTCCTCGGTCATGTAGATGAACTAGGAACAGTTTCAAAAATAAATGAAACAGCC AATGCCAAAATTATTACGATTCAATGTAGCCAACATATTAATAATCAGTTAGTTAAGCAAGGGTCTATT ACTGTGGATGGTGTAAGTCTAACGGTATTTGATAAGCATGATAACAGTTTTGACATTCATCTTATTCCA GAAACGAGGCGTTCAACGATTTTATCATCCAAAAAATTAGGAGATAAAGTACATTTAGAAACAGACGTT TTGTTTAA ATATGTTGAAAATATTTTAAATAAAGATAAAGACCAATTATCTGTAGATAAATTAAGAGCATTTGGTTT TTAG- 3 ' (B) Staphylococcus aureus nbB polypeptide sequence deduced from the polynucleotide sequence in this table [SEQ ID NO 2] NH ? - MFTGIVEEI GWKSVQI RQSVRTI EIEAHKITADMHI GDS I SVNGACLTVI DFDQTS FTVQVIKSTENK TY ADVKRQSEVNLER- AMSGNGRFGGHFV GHVDELGTVSKINETANAKIITIQCSQHINNQLVKQGSI TVDGVSLTVFDKHDNSFDIHLI PETRRSTI LS SKKLGDKVHLETDVLFKYVENI LNKDKDQLSVDKLRA FGF-COOH (C) Polynucleotide sequences comprising Staphylococcus aureus nbB ORF sequence [SEQ ID NO 3] 5 ' - AGCATCTTTCCTGTCAAGTAATAAAGCCTTGAAATAAACCTATTAGCAGNTGTAAGCGCCAATCAGAAG TAATTTAGANCTTCCATGAGTGTANCGGTAGGTTTGGTGGACATTTTTCCTCGGTCATGTAGTGACTAG GACANTTCACAAATAAATGAAACACCAATGCCACAATTATTNCGATTCAATGTAGCCAACATATTAATA ATCAGTTAGTTAAGCAAGGTCTATTACTGTGGATGGTGTAAGTCTAGCGGTATTTGATAAGCATGATAA CAGTTTTGACATTCATCTTATTCCAGAAACGAGGCGTTCAACGATTTTATCATCCACAAAATTAGGAGA TAAAGTACATTTAGAAACAGACGTTTTGTTTAAATATGTTGAAAATATTTTAAATAAAGATAAAGACCA ATTATCTGTAGATAAATTAAGAGCATTTGGNTTTTAGGAGGGGTAGCATGCAATTCGATAATAGGAATT C -3 ' (D) Staphylococcus aureus ribB polypeptide sequence deduced from the polynucleotide ORF sequence in this table [SEQ ID NO 4] NH 2 - VDGVSLAVFDKHDNSFDIHLI PETRRSTILSSTKLGDKλ HLETDVLFKYVENILNKDKDQLSVDKLRAF XF -COOH Deposited materials A deposit containing a Staphylococcus aureus WCUH 29 str-ain has been deposited with the National Collections of Industnal and Marine Bactena Ltd (herem "NCIMB"), 23 St Machar Dπve, Aberdeen AB2 1RY, Scotland on 11 September 1995 and assigned NCIMB Deposit No 40771 , and refened to as Staphylococcus aureus WCUH29 on deposit The Staphylococcus aureus stra deposit is refened to herem as "the deposited stram" or as "the DNA of the deposited stram " The deposited strain contains the full length nbB gene The sequence of the polynucleotides contained m the deposited strain, as well as the ammo acid sequence of the polypeptide encoded thereby, are controlling in the event of .any conflict with .any descnption of sequences herem The deposit of the deposited strain has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure The stram will be irrevocably and without restnction or condition released to the public upon the issuance of a patent The deposited stram is provided merely as convemence to those of skill m the art and is not an admission that a deposit is required for enablement, such as that required under 35 U S C §112 A license may be required to make, use or sell the deposited strain, .and compounds denved therefrom, .and no such license is hereby granted One aspect of the mvention there is provided .an isolated nucleic acid molecule encoding a mature polypeptide expressible by the Stαphylococcus αureus WCUH 29 stram contained m the deposited stram Further provided by the mvention are nbB nucleotide sequences of the DNA in the deposited stram and ammo acid sequences encoded thereby Also provided by the mvention are nbB polypeptide sequences isolated from the deposited stram and ammo acid sequences denved therefrom Polypeptides The polypeptides of the mvention include a polypeptide of Table 1 [SEQ ID NO 2 or 4] (in particular the mature polypeptide) as well as polypeptides and fragments, particularly those which have the biological activity of nbB. .and also those which have at least 70% identity to a polypeptide of Table 1 [SEQ ID NO 1 or 3]or the relevant portion, preferably at least 80% identity to a polypeptide of Table 1 [SEQ ID NO 2 or 4and more preferably at least 90% similanty (more preferably at least 90% identity) to a polypeptide of Table 1 [SEQ ID NO 2 or 4] and still more preferably at least 95 % similanty (still more preferably at least 95% identity) to a polypeptide of Table 1 [SEQ ID NO 2 or 4] and also mclude portions of such polypeptides with such portion of the polypeptide generally containing at least 30 ammo acids and more preferably at least 50 ammo acids The mvention also mcludes polypeptides of the formula X-(R 1 ) m -(R 2 )-(R 3 ) n -Y wherem, at the .amino terminus. X is hydrogen, and at the carboxyl terminus, Y is hydrogen or a metal, R\ .and R3 are any ammo acid residue, m is an mteger between 1 and 1000 or zero, n is an integer between 1 and 1000 or zero, .and R 2 is .an ammo acid sequence of the mvention, particularly an .ammo acid sequence selected from Table 1 In the formula above R 2 is onented so that its ammo terminal residue is at the left, bound to Rj .and its carboxy terminal residue is at the nght, bound to R3 Any stretch of ammo acid residues denoted by either R group, where m and/or n is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer A fragment is a vanant polypeptide having an ammo acid sequence that entirely is the same as part but not all of the .ammo acid sequence of the aforementioned polypeptides As with nbB polypeptides fragments may be "free-standing," or compnsed within a larger polypeptide of which they form a part or region, most preferably as a smgle continuous region, a single larger polypeptide Prefened fragments mclude, for example, truncation polypeptides having a portion of an ammo acid sequence of Table 1 [SEQ ID NO 2 or 4], or of vanants thereof, such as a contmuous seπes of residues that mcludes the ammo terminus, or a contmuous senes of residues that mcludes the carboxyl terminus Degradation forms of the polypeptides of the mvention m a host cell, particularly a Staphylococcus aureus, are also prefened Further prefened .are fragments charactenzed by structural or functional attributes such as fragments that compnse alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophi c regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high .antigemc index regions Also prefened .are biologically active fragments which are those fragments that mediate activities of nbB. including those with a similar activity or an improved activity, or with a decreased undesirable activity Also mcluded are those fragments that are antigemc or lmmunogenic m an animal, especially m a human Particularly prefened are fragments compπsmg receptors or domains of enzymes that confer a function essential for viability of Stαphylococcus αureus or the ability to initiate, or maintain cause disease m an individual, particularly a human Vanants that are fragments of the polypeptides of the mvention may be employed for producing the coπesponding full-length polypeptide by peptide synthesis, therefore, these vanants may be employed as intermediates for producmg the full-length polypeptides of the mvention In addition to the standard single and triple letter representations for amino acids, the term "X" or "Xaa" may also be used in describing certain polypeptides of the invention "X" and "Xaa" mean that any of the twenty naturally occuπng amino acids may appear at such a designated position m the polypeptide sequence Polynucleotides Another .aspect of the mvention relates to isolated polynucleotides, including the full length gene, that encode the nbB polypeptide hav g a deduced ammo acid sequence of Table 1 [SEQ ID NO 2 or 4] and polynucleotides closely related thereto and vanants thereof Usmg the information provided herem. such as a polynucleotide sequence set out m Table 1 [SEQ ID NO 1 or 3], a polynucleotide of the mvention encoding nbB polypeptide may be obtained usmg standard cloning and screening methods, such as those for cloning .and sequencmg chromosomal DNA fragments from bactena usmg Staphylococcus aureus WCUH 29 cells as starting matenal, followed by obtaining a full length clone For example, to obtain a polynucleotide sequence of the invention, such as a sequence given in Table 1 [SEQ ID NO 1 or 3], typically a library of clones of chromosomal DNA of Stαphylococcus αureus WCUH 29 in E coh or some other suitable host is probed with a radiolabeled ohgonucleotide, preferably a 17-mer or longer, derived from a partial sequence Clones carrying DNA identical to that of the probe can then be distinguished using stringent conditions By sequencing the individual clones thus identified with sequencing primers designed from the original sequence it is then possible to extend the sequence m both directions to determine the full gene sequence Conveniently, such sequencing is performed using denatured double stranded DNA prepared from a plasmid clone Suitable techniques are described by Mamatis, T , Fntsch, E F and Sambrook et al , MOLECULAR CLONING, A LABORATORY MANUAL, 2nd Ed . Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989) (see in particular Screening By Hybridization 1 90 and Sequencing Denatured Double-Stranded DNA Templates 13 70) Illustrative of the mvention, the polynucleotide set out in Table 1 [SEQ ID NO 1 or 3] was discovered m a DNA library denved from Stαphylococcus αureus WCUH 29 The DNA sequence set out m Table 1 [SEQ ID NO 1 or 3] contains an open reading frame encoding a protem havmg about the number of am o acid residues set forth m Table 1 [SEQ ID NO 2 or 4] with a deduced molecular weight that can be calculated usmg ammo acid residue molecular weight values well known in the art The polynucleotide of SEQ ID NO 1, between nucleotide number 1 and the stop codon which begins at nucleotide number 631 of SEQ ID NO 1, encodes the polypeptide of SEQ ID NO 2 RibB of the mvention is structurally related to other proteins of the nboflavin synthase (α- subunit) family See Swiss Prot Accession No P50854, GenBank Accession No U27202 Also see Perkins, JB et al In Bacillus subtihs and Other Gram-Positive Bacteria Eds Sonenshem, AL, Hoch, JA .and Losick, R 1993 American Society for Microbiology The mvention provides a polynucleotide sequence identical over its entire length to a coding sequence m Table 1 [SEQ ID NO 1 or 3] Also provided by the mvention is the coding sequence for the mature polypeptide or a fragment thereof, by itself as well as the coding sequence for the mature polypeptide or a fragment m reading frame with other coding sequence, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protem sequence The polynucleotide may also contam non-codmg sequences, mcludmg for example, but not limited to non-codmg 5 ' and 3 ' sequences, such as the transcnbed, non-translated sequences, termination signals, nbosome binding sites, sequences that stabilize mRNA, introns, polyadenylation signals, and additional coding sequence which encode additional ammo acids For example, a marker sequence that facilitates punfication of the fused polypeptide can be encoded hi certain embodiments of the mvention. the marker sequence is a hexa-histidme peptide. as provided m the pQE vector (Qiagen, Inc ) .and descnbed in Gentz et al , Proc Natl Acad Sa , USA 86 821-824 (1989). or an HA tag (Wilson et al , Cell 37 767 (1984) Polynucleotides of the mvention also mclude. but are not limited to, polynucleotides compnsing a structural gene .and its naturally associated sequences that control gene expression A prefened embodiment of the mvention is a polynucleotide of compnsmg nucleotide 1 to the nucleotide rmmediately upstream of or mcludmg nucleotide 631 set forth m SEQ ID NO 1 of Table 1, both of which encode the nbB polypeptide The mvention also mcludes polynucleotides of the formula X-(R 1 ) m -(R 2 )-(R 3 ) n -Y wherem. at the 5' end of the molecule, X is hydrogen, and at the 3' end of the molecule, Y is hydrogen or a metal, R j .and R3 is any nucleic acid residue, m is an integer between 1 and 3000 or zero . n is an integer between 1 and 3000 or zero, and R is a nucleic acid sequence of the mvention, p.artιcularly a nucleic acid sequence selected from Table 1 In the polynucleotide formula above R 2 is onented so that its 5' end residue is at the left, bound to Ri .and its 3' end residue is at the nght, bound to R3 Any stretch of nucleic acid residues denoted by either R group, where m and/or n is greater th.an 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer In a prefened embodiment m and/or n is an mteger between 1 .and 1000. It is most prefened that the polynucleotides of the inventions .are denved from Staphylococcus aureus, however, they may preferably be obtamed from organisms of the same taxonomic genus They may also be obtamed, for example, from orgamsims of the same taxonomic family or order The term "polynucleotide encodmg a polypeptide" as used herem encompasses polynucleotides that mclude a sequence encodmg a polypeptide of the mvention, particularly a bactenal polypeptide and more particularly a polypeptide of the Staphylococcus aureus nbB havmg an ammo acid sequence set out m Table 1 [SEQ ID NO 2 or 4J The term also encompasses polynucleotides that mclude a smgle contmuous region or discontinuous regions encodmg the polypeptide (for example, interrupted by integrated phage or an insertion sequence or editing) together with additional regions, that also may contam coding .and/or non-coding sequences The mvention further relates to vanants of the polynucleotides descπbed herem that encode for vanants of the polypeptide havmg a deduced ammo acid sequence of Table 1 [SEQ ID NO 2 or 4] Vanants that are fragments of the polynucleotides of the mvention may be used to synthesize full- length polynucleotides of the mvention Further particularly prefened embodiments are polynucleotides encodmg nbB vanants. that have the ammo acid sequence of nbB polypeptide of Table 1 [SEQ ID NO 2 or 4] in which several, a few, 5 to 10, 1 to 5, 1 to 3. 2. 1 or no ammo acid residues are substituted, deleted or added, in any combination Especially prefened among these are silent substitutions, additions and deletions, that do not alter the properties .and activities of nbB Further preferred embodiments of the mvention are polynucleotides that are at least 70% identical over their entire length to a polynucleotide encodmg nbB polypeptide havmg an ammo acid sequence set out m Table 1 [SEQ ID NO 2 or 4], and polynucleotides that are complementary to such polynucleotides Alternatively, most highly prefened are polynucleotides that compnse a region that is at least 80%> identical over its entire length to a polynucleotide encodmg nbB polypeptide and polynucleotides complementary thereto In this regard, polynucleotides at least 90%> identical over their entire length to the s.ame are particularly prefened, and among these particularly prefened polynucleotides, those with at least 95% are especially prefened Furthermore, those with at least 97% are highly prefened among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly prefened, with at least 99% bemg the more prefened Prefened embodiments are polynucleotides that encode polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by a DNA of Table 1 [SEQ ID NO 1 or 3] The mvention further relates to polynucleotides that hybndize to the herem above-descnbed sequences In this regard, the mvention especially relates to polynucleotides that hybndize under stringent conditions to the herem above-descnbed polynucleotides As herem used, the terms "stringent conditions" and "stringent hybndization conditions" mean hybndization will occur only if there is at least 95% and preferably at least 97% identity between the sequences An example of stringent hybridization conditions is overnight incubation at 42°C m a solution comprising 50%) formamide, 5x SSC (150 mM NaCl, 15 mM tπsodium citrate), 50 mM sodium phosphate (pH7 6), 5x Denhardt's solution, 10% dextran sulfate. and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the hybridization support in 0 lx SSC at about 65 °C Hybridization and wash conditions are well known and exemplified in Sambrook, et al , Molecular Cloning A Laboratory Manual, Second Edition. Cold Spring Harbor, N Y , (1989), particularly Chapter 11 therein The invention also provides a polynucleotide consisting essentially of a polynucleotide sequence obtainable by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO 1 under stringent hybridization conditions with a probe havmg the sequence of said polynucleotide sequence set forth in SEQ ID NO 1 or a fragment thereof, and isolating said DNA sequence Fragments useful for obtaining such a polynucleotide mclude, for example, probes and primers described elsewhere herem As discussed additionally herem regarding polynucleotide assays of the mvention, for instance, polynucleotides of the mvention as discussed above, may be used as a hybndization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding nbB and to isolate cDNA and genomic clones of other genes that have a high sequence similanty to the nbB gene Such probes generally will compπse at least 15 bases Preferably, such probes will have at least 30 bases and may have at least 50 bases Particularly prefened probes will have at least 30 bases and will have 50 bases or less For example, the coding region of the nbB gene may be isolated by screening usmg a DNA sequence provided m Table 1 [SEQ ID NO 1 or 3] to synthesize an o gonucleotide probe A labeled ohgonucleotide havmg a sequence complementary to that of a gene of the mvention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybndizes to The polynucleotides and polypeptides of the mvention may be employed, for example, as research reagents and mateπals for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herem relatmg to polynucleotide assays Polynucleotides of the invention that are ohgonucleotides derived from the sequences of Table 1 [SEQ ID NOS 1 or 2 or 3 or 4] may be used m the processes herein as described, but preferably for PCR, to determine whether or not the polynucleotides identified herein in whole or in part are transcribed in bacteria in infected tissue It is recognized that such sequences will also have utility m diagnosis of the stage of infection and type of infection the pathogen has attained The mvention also provides polynucleotides that may encode a polypeptide that is the mature protem plus additional ammo or carboxyl-terminal ammo acids, or ammo acids mtenor to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance) Such sequences may play a role m processmg of a protem from precursor to a mature form, may allow protem transport, may lengthen or shorten protem half-life or may facilitate manipulation of a protem for assay or production, among other things As generally is the case in vivo, the additional ammo acids may be processed away from the mature protem by cellular enzymes A precursor protem. havmg the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide When prosequences are removed such inactive precursors generally are activated Some or .all of the prosequences may be removed before activation Generally, such precursors are called proproteins In addition to the standard A, G, C, T/U representations for nucleic acid bases, the term "N" may also be used in descπbmg certain polynucleotides of the mvention "N" means that any of the four DNA or RNA bases may appear at such a designated position m the DNA or RNA sequence, except it is preferred that N is not a base that when tiiken in combination with adjacent nucleotide positions, when read m the correct reading frame, would have the effect of generating a premature termination codon m such reading frame In sum. a polynucleotide of the mvention may encode a mature protem, a mature protem plus a leader sequence (which may be refened to as a preprotein), a precursor of a mature protem havmg one or more prosequences that are not the leader sequences of a preprotem, or a preproprotein, which is a precursor to a proprotem, havmg a leader sequence and one or more prosequences, which generally are removed during processmg steps that produce active and mature forms of the polypeptide Vectors, host cells, expression The mvention also relates to vectors that compnse a polynucleotide or polynucleotides of the mvention, host cells that are genetically engmeered with vectors of the mvention and the production of polypeptides of the mvention by recombinant techniques Cell-free translation systems can also be employed to produce such proteins usmg RNAs denved from the DNA constructs of the mvention For recombinant production, host cells can be genetically engmeered to incorporate expression systems or portions thereof or polynucleotides of the mvention Introduction of a polynucleotide mto the host cell can be effected by methods descnbed in many standard laboratory manuals, such as Davis et al , BASIC METHODS IN MOLECULAR BIOLOGY, (1986) and Sambrook et al , MOLECULAR CLONING A LABORATORY MANUAL, 2nd Ed , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N Y (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic hpid- mediated transfection, electroporation, transduction, scrape loading, ballistic mtroduction and infection Representative examples of appropnate hosts mclude bactenal cells, such as streptococci, staphylococci. enterococci E coli, streptomyces and Bacillus subtihs cells, fungal cells, such as yeast cells and Aspergillus cells, msect cells such as Drosophila S2 and Spodoptera Sf9 cells, animal cells such as CHO, COS. HeLa. C127. 3T3. BHK. 293 and Bowes melanoma cells, and plant cells A great vanety of expression systems can be used to produce the polypeptides of the mvention Such vectors mclude, among others, chromosomal, episomal and vmis-denved vectors, e g , vectors denved from bacteπal plasmids, from bactenophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses. and vectors denved from combmations thereof, such as those denved from plasmid .and bactenophage genetic elements, such as cosmids and phagemids The expression system constructs may contam control regions that regulate as well as engender expression Generally, any system or vector suitable to maintain, propagate or express polynucleotides .and/or to express a polypeptide m a host may be used for expression m this regard The appropriate DNA sequence may be inserted into the expression system by .any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL, (supra). For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals. Polypeptides of the invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding protein may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification. Diagnostic Assays This invention is also related to the use of the ribB polynucleotides of the invention for use as diagnostic reagents. Detection of ribB in a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of a disease. Eukaryotes (herein also "individual(s)"), particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism comprising the ribB gene may be detected at the nucleic acid level by a variety of techniques. Nucleic acids for diagnosis may be obtained from .an infected individu 's cells and tissues, such as bone, blood, muscle, cartilage, and skin. Genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other .amplification technique prior to analysis. RNA, cDNA and genomic DNA may also be used in the same ways. Using amplification, characterization of the species and strain of prokaryote present in an individual, may be made by an analysis of the genotype of the prokaryote gene. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the genotype of a reference sequence. Point mutations can be identified by hybridizing amplified DNA to labeled ribB polynucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in the electrophoretic mobility of the DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing See, e g , Myers et .al , Science, 230 1242 (1985) Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and S 1 protection or a chemical cleavage method See, e g , Cotton et al , Proc Natl Acad Sci , USA, 85 4397-4401 (1985) Cells carrying mutations or polymorphisms in the gene of the mvention may also be detected at the DNA level by a vanety of techniques, to .allow for serotyping, for example For example, RT- PCR can be used to detect mutations It is particularly prefened to used RT-PCR m conjunction with automated detection systems, such as, for example, GeneScan RNA, cDNA or genomic DNA may also be used for the same purpose, PCR or RT-PCR As an example, PCR primers complementary to a nucleic acid encodmg nbB can be used to identify and analyze mutations Examples of representative primers are shown below m Table 2 Table 2 Primers for amplification of ribB polynucleotides SEQ ID NO PRIMER SEQUENCE 5 5'-TCGTTGAAGAAATAGGTGTCGT-3' 6 5'-GGCATTGGCTGTTTCATTTAT-3' The mvention also mcludes primers of the formula X-(R 1 ) m -(R 2 )-(R 3 ) n -Y wherem, at the 5' end of the molecule, X is hydrogen, and at the 3' end of the molecule. Y is hydrogen or a metal, R\ and R3 is .any nucleic acid residue, m is an integer between 1 .and 20 or zero , n is an mteger between 1 and 20 or zero, and R 2 is a primer sequence of the mvention, particularly a primer sequence selected from Table 2 In the polynucleotide formula above R 2 is onented so that its 5' end residue is at the left, bound to Rj and its 3' end residue is at the nght, bound to R3 Any stretch of nucleic acid residues denoted by either R group, where m and/or n is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer being complementary to a region of a polynucleotide of Table 1 In a prefened embodiment m and/or n is an mteger between 1 and 10. The mvention further provides these primers with 1, 2, 3 or 4 nucleotides removed from the 5' .and/or the 3' end These primers may be used for, among other things, amplifying nbB DNA isolated from a sample denved from an individual The primers may be used to amplify the gene isolated from an infected individual such that the gene may then be subject to vanous techniques for elucidation of the DNA sequence In this way, mutations in the DNA sequence may be detected and used to diagnose infection and to serotype and/or classify the infectious agent The mvention further provides a process for diagnosing, disease, preferably bacterial infections, more preferably infections by Staphylococcus aureus, comprising determmmg from a sample derived from an individual a increased level of expression of polynucleotide havmg a sequence of Table 1 [SEQ ID NO 1 or 3] Increased or decreased expression of nbB polynucleotide can be measured using any on of the methods well known in the art for the quantation of polynucleotides, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods In addition, a diagnostic assay in accordance with the mvention for detectmg over- expression of nbB protem compared to normal control tissue samples may be used to detect the presence of an infection, for example Assay techniques that can be used to determine levels of a nbB protem, in a sample denved from a host are well-known to those of skill m the art Such assay methods mclude radioimmunoassays. competitive-binding .assays, Western Blot analysis and ELISA assays Antibodies The polypeptides of the mvention or vanants thereof, or cells expressing them can be used as an unmunogen to produce antibodies lmmunospecific for such polypeptides "Antibodies" as used herem mcludes monoclonal and polyclonal antibodies, chimenc, smgle chain, simiamzed .antibodies and humamzed antibodies, as well as Fab fragments, mcludmg the products of an Fab lmmunolglobuhn expression library Antibodies generated against the polypeptides of the mvention can be obtamed by administeπng the polypeptides or epitope-beaπng fragments, analogues or cells to an animal, preferably a nonhuman, usmg routme protocols For preparation of monoclonal antibodies, any technique known in the .art that provides antibodies produced by contmuous cell lme cultures can be used Examples mclude vanous techniques, such as those m Kohler, G and Milstein, C , Nature 256 495-497 (1975), Kozbor et al , Immunology Today 4 72 (1983), Cole et al , pg 77-96 in MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R Liss, Inc (1985) Techniques for the production of smgle cham antibodies (U S Patent No 4,946,778) can be adapted to produce smgle cham antibodies to polypeptides of this mvention Also, transgemc mice, or other organisms such as other mammals, may be used to express humanized .antibodies Alternatively phage display technology may be utilized to select antibody genes with binding activities towards the polypeptide either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing anti-πbB or from naive libraries (McCafferty, J et al . (1990), Nature 348, 552-554, Marks, J et al , (1992) Biotechnology 10, 779-783) The affinity of these antibodies can also be improved by chain shuffling (Clackson, T et al , (1991) Nature 352, 624-628) If two antigen binding domains are present each domain may be directed against a different epitope - termed 'bispecific' antibodies The above-descnbed antibodies may be employed to isolate or to identify clones expressmg the polypeptides to punfy the polypeptides by affinity chromatography Thus, among others, antibodies agamst nbB- polypeptide may be employed to treat infections, particularly bactenal infections Polypeptide variants include antigenically, epitopically or immunologically equivalent variants that form a particular aspect of this invention The term "antigenically equivalent derivative" as used herein encompasses a polypeptide or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protem or polypeptide according to the invention, interfere with the immediate physical interaction between pathogen and mammalian host The term "immunologically equivalent derivative" as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the immediate physical interaction between pathogen and mammalian host The polypeptide, such as an antigenically or immunologically equivalent derivative or a fusion protem thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken The fusion protem may provide stability to the polypeptide The antigen may be associated, for example by conjugation, with an immunogenic earner protein for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH) Alternatively a multiple antigemc peptide comprising multiple copies of the protein or polypeptide. or an antigenically or immunologically equivalent polypeptide thereof may be sufficiently antigemc to improve lmmunogenicity so as to obviate the use of a carrier Preferably, the antibody or variant thereof is modified to make it less immunogenic in the individual For example, if the individual is human the antibody may most preferably be "humanized", where the comphmentaπty determining regιon(s) of the hybπdoma-deπved antibody has been transplanted into a human monoclonal antibody , for example as described in Jones, P et al (1986). Nature 321, 522-525 or Tempest et al , (1991) Biotechnology 9, 266-273 The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff et al , Hum Mol Genet 1992, 1 363. Manthorpe et al , Hum Gene Ther 1963 4, 419), delivery of DNA complexed with specific protein carriers (Wu et al , J Biol Chem 1989 264,16985), coprecipitation of DNA with calcium phosphate (Benvemsty & Reshef, PNAS USA 1986 83,9551), encapsulation of DNA in various forms of liposomes (Kaneda et al , Science 1989 243,375), particle bombardment (Tang et al , Nature 1992, 356 152, Eisenbraun et al , DNA Cell Biol 1993, 12 791) and in vivo infection using cloned retroviral vectors (Seeger et al , PNAS USA 1984 81,5849) Antagonists and agonists - assays and molecules Polypeptides of the mvention may also be used to assess the binding of small molecule substrates and ligands m, for example, cells, cell-free preparations, chemical libranes, and natural product mixtures These substrates and ligands may be natural substrates and ligands or may be structural or functional πumetics See, e g . Cohgan et al , Current Protocols in Immunology 1 (2) Chapter 5 (1991) The mvention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of nbB polypeptides or polynucleotides, particularly those compounds that are bactenostatic and/or bactenocidal The method of screening may involve high-throughput techniques For example, to screen for agomsts or antagoists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, compπsmg nbB polypeptide and a labeled substrate or ligand of such polypeptide is mcubated in the absence or the presence of a candidate molecule that may be a nbB agomst or antagonist The ability of the candidate molecule to agonize or antagonize the nbB polypeptide is reflected m decre^ed binding of the labeled ligand or decreased production of product from such substrate Molecules that b d gratuitously, ; e , without mducmg the effects of nbB polypeptide are most likely to be good antagonists Molecules that bmd well and increase the rate of product production from substrate are agomsts Detection of the rate or level of production of product from substrate may be enhanced by usmg a reporter system Reporter systems that may be useful in this regard mclude but are not limited to colonmetnc labeled substrate converted mto product, a reporter gene that is responsive to changes m nbB polynucleotide or polypeptide activity, and binding assays known m the art Another example of an assay for nbB antagonists is a competitive assay that combines nbB and a potential antagonist with nbB-binding molecules, recombinant nbB bmding molecules, natural substrates or ligands. or substrate or ligand mimetics, under appropnate conditions for a competitive inhibition assay RibB can be labeled, such as by radioactivity or a coloπmetπc compound, such that the number of nbB molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist Potential antagonists mclude small orgamc molecules, peptides, polypeptides and antibodies that bmd to a polynucleotide or polypeptide of the mvention and thereby inhibit or extinguish its activity Potential antagonists also may be small orgamc molecules, a peptide, a polypeptide such as a closely related protem or antibody that bmds the same sites on a binding molecule, such as a binding molecule, without mducmg nbB-induced activities, thereby preventmg the action of nbB by excluding nbB from binding Potential antagonists mclude a small molecule that bmds to and occupies the binding site of the polypeptide thereby preventmg binding to cellular binding molecules, such that normal biological activity is prevented Examples of small molecules mclude but are not limited to small organic molecules, peptides or peptide-like molecules Other potential antagonists mclude antisense molecules (see Okano, ./ Neurochem 56 560 (1991), OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION. CRC Press. Boca Raton. FL (1988), for a descπption of these molecules) Prefened potential antagonists mclude compounds related to and vanants of nbB Each of the DNA sequences provided herem may be used in the discovery and development of antibacterial compounds The encoded protem, upon expression, can be used as a target for the screemng of antibacterial drugs Additionally, the DNA sequences encodmg the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the codmg sequence of interest The invention also provides the use of the polypeptide, polynucleotide or inhibitor of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection In particular the molecules of the invention may be used in the prevention of adhesion of bacteria, in particular gram positive bacteria, to mammalian extracellular matrix proteins on m-dwelhng devices or to extracellular matrix proteins in wounds, to block nbB protein-mediated mammalian cell invasion by, for example, initiating phosphorylation of mammalian tyrosine kinases (Rosenshine et al , Infect Immun 60 2211 (1992), to block bacterial adhesion between mammalian extracellular matrix proteins and bacterial nbB proteins that mediate tissue damage and. to block the normal progression of pathogenesis in infections initiated other than by the implantation of m-dwelhng devices or by other surgical techniques The antagonists and agomsts of the mvention may be employed, for instance, to inhibit and treat diseases Hehcobacter pylori (herem H pylori) bacteria mfect the stomachs of over one-third of the world's population causing stomach cancer, ulcers, and gastritis (International Agency for Research on Cancer (1994) Schistosomes, Liver Flukes and Hehcobacter Pylori (International Agency for Research on Cancer, Lyon, France, http //www uicc ch/ecp/ecp2904 htm) Moreover, the international Agency for Research on Cancer recently recognized a cause-and- effect relationship between H pylori and gastric adenocarcmoma, classifying the bacterium as a Group I (definite) carcinogen Preferred antimicrobial compounds of the invention (agomsts and antagomsts of nbB) found using screens provided by the invention, particularly broad- spectrum antibiotics, should be useful in the treatment of H pylori infection Such treatment should decrease the advent of H /jy/orz-induced cancers, such as gastrointestinal carcinoma Such treatment should also cure gastric ulcers and gastritis Vaccines Another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal which comprises inoculating the individual with nbB, or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said individual from infection, particularly bacterial infection and most particularly Staphylococcus aureus infection Also provided are methods whereby such immunological response slows bacterial replication Yet another aspect of the invention relates to a method of inducing immunological response in an individual which comprises delivering to such individual a nucleic acid vector to direct expression of nbB, or a fragment or a variant thereof, for expressing nbB, or a fragment or a variant thereof in vivo m order to induce an immunological response, such as, to produce antibody and/ or T cell immune response, including, for example, cytokine-producmg T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established withm the individual or not One way of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid A further aspect of the invention relates to an immunological composition which, when introduced into an individual capable or having induced within it an immunological response, induces an immunological response in such individual to a nbB or protem coded therefrom, wherem the composition comprises a recombinant nbB or protem coded therefrom comprising DNA which codes for and expresses an antigen of said nbB or protein coded therefrom The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+ T cells A nbB polypeptide or a fragment thereof may be fused with co-protem which may not by itself produce antibodies, but is capable of stabilizing the first protem and producing a fused protein which will have immunogenic and protective properties Thus fused recombinant protein, preferably further comprises an antigemc co-protein, such as hpoprotein D from Hemophilus mfluenzae, Glutathione-S -transferase (GST) or beta-galactosidase, relatively large co-proteins which solubihze the protem and facilitate production and purification thereof Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system The co-protem may be attached to either the amino or carboxy terminus of the first protem Provided by this invention are compositions, particularly vaccine compositions, and methods comprising the polypeptides or polynucleotides of the mvention and lmmunostimulatory DNA sequences, such as those described in Sato, Y et al Science 273 352 (1996) Also, provided by this invention are methods using the described polynucleotide or particular fragments thereof which have been shown to encode non-variable regions of bacterial cell surface proteins in DNA constructs used in such genetic immunization experiments in animal models of infection with Staphylococcus aureus will be particularly useful for identifying protem epitopes able to provoke a prophylactic or therapeutic immune response It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resisting or clearing infection for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly Staphylococcus aureus infection, in mammals, particularly humans The polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacteria, for example by blocking adherence of bacteria to damaged tissue Examples of tissue damage include wounds m skm or connective tissue caused, e g . by mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagma The invention also mcludes a vaccine formulation which compπses an immunogenic recombinant protem of the mvention together with a suitable carrier Smce the protein may be broken down in the stomach, it is preferably administered parenterally. including, for example, administration that is subcutaneous, intramuscular, intravenous, or intradermal Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contam anti-oxidants, buffers, bacteπostats .and solutes which render the formulation insotonic with the bodily fluid, preferably the blood, of the individual, and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents The formulations may be presented m unit-dose or multi-dose containers, for example, sealed ampules and vials and may be stored in a freeze-dπed condition requiring only the addition of the sterile liquid carrier immediately prior to use The vaccine formulation may also mclude adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known m the art The dosage will depend on the specific activity of the vaccme and can be readily determined by routine expenmentation While the invention has been described with reference to certain nbB protem, it is to be understood that this covers fragments of the naturally occumng protem and similar proteins with additions, deletions or substitutions which do not substantially affect the immunogenic properties of the recombinant protein Compositions, kits .and administration The mvention also relates to compositions compnsmg the polynucleotide or the polypeptides discussed above or their .agonists or antagonists The polypeptides of the mvention may be employed in combination with a non-stenle or stenle earner or earners for use with cells, tissues or organisms, such as a pharmaceutical earner suitable for administration to a subject Such compositions compnse, for instance, a media additive or a therapeutically effective amount of a polypeptide of the mvention and a pharmaceutically acceptable earner or excipient Such earners may mclude, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof The formulation should suit the mode of administration The mvention further relates to -diagnostic and pharmaceutical packs and kits compnsmg one or more containers filled with one or more of the ingredients of the aforementioned compositions of the mvention Polypeptides and other compounds of the mvention may be employed alone or m conjunction with other compounds, such as therapeutic compounds The pharmaceutical compositions may be administered m .any effective, convement manner mcludmg, for instance, administration by topical, oral, anal, vaginal, mtravenous, mtrapentoneal, intramuscular, subcutaneous, mtranasal or intradermal routes among others In therapy or as a prophylactic, the active agent may be administered to an individual as an mjectable composition, for example as a sterile aqueous dispersion, preferably isotonic Alternatively the composition may be formulated for topical application for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contam appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions Such carriers may constitute from about 1% to about 98 > by weight of the formulation, more usually they will constitute up to about 80% by weight of the formulation For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0 01 mg/kg to 10 mg/kg, typically around 1 mg/kg The physician m any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual The above dosages are exemplary of the average case There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are withm the scope of this invention In-dwelling devices include surgical implants, prosthetic devices and catheters, I e . devices that are introduced to the body of an individual and remain in position for an extended tune Such devices include, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrospmal fluid shunts, urinary catheters, continuous ambulatory peritoneal dialysis (CAPD) catheters The composition of the invention may be administered by injection to achieve a systemic effect against relevant bacteria shortly before insertion of an m-dwelhng device Treatment may be continued after surgen during the in-body time of the device In addition, the composition could also be used to broaden peπoperative cover for .any surgical technique to prevent bacterial wound infections, especially Staphylococcus aureus wound infections Many orthopaedic surgeons consider that humans with prosthetic joints should be considered for antibiotic prophylaxis before dental treatment that could produce a bacteremia Late deep infection is a serious complication sometimes leading to loss of the prosthetic joint and is accompanied by significant morbidity and mortality It may therefore be possible to extend the use of the active agent as a replacement for prophylactic antibiotics in this situation In addition to the therapy described above, the compositions of this mvention may be used generally as a wound treatment agent to prevent adhesion of bacteria to matrix protems exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or in conjunction with, antibiotic prophylaxis Alternatively, the composition of the invention may be used to bathe an indwelling device immediately before insertion The active agent will preferably be present at a concentration of lμg/ml to lOmg/ml for bathing of wounds or indwelling devices A vaccine composition is conveniently in mjectable form Conventional adjuvants may be employed to enhance the immune response A suitable unit dose for vaccination is 0 5-5 microgram/kg of .antigen, .and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals Each reference disclosed herem is incorporated by reference herem in its entirety Any patent application to which this application claims priority is also incorporated by reference herem m its entirety GLOSSARY The following definitions are provided to facilitate understanding of certain terms used frequently herem "Dιsease(s)" means and disease caused by or related to infection a bactena. mcludmg disease, such as, infections of the upper respiratory tract (e g , otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e g , empyema, lung abscess), cardiac (e g , infective endocarditis), gastrointestinal (e g , secretory diaπhoea, splemc absces, retropentoneal abscess), CNS (e g , cerebral abscess), eye (e g , blephantis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital cellulitis, darcryocystitis), kidney and urinary tract (e g . epididymitis, intrarenal and pennephnc absces, toxic shock syndrome), skin (e g , impetigo, folhculitis. cutaneous abscesses, cellulitis, wound infection, bactenal myositis) bone and joint (e g , septic arthntis, osteomyelitis) "Host cell" is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence "Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between stπngs of such sequences "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (Computational Molecular Biology. Lesk. A M , ed , Oxford University Press. New York, 1988, Biocomputmg Informatics and Genome Projects, Smith, D W , ed . Academic Press, New York, 1993. Computer Analysis of Sequence Data, Part I, Griffin. A M . and Griffin, H G , eds Humana Press, New Jersey, 1994 Sequence Analysis in Molecular Biology, von Heinje, G . Academic Press, 1987. and Sequence Analysis Primer, Gπbskov, M and Devereux, J , eds . M Stockton Press, New York, 1991 .and Caπllo, H , and Lipman, D , SLAM J Applied Math , 48 1073 (1988) Preferred methods to determine identity are designed to give the largest match between the sequences tested Methods to determine identity and similarity are codified in publicly available computer programs Preferred computer program methods to determine identity and similarity between two sequences mclude, but are not limited to, the GCG program package (Devereux, J , et al , Nucleic Acids Research 12(1) 387 (1984)), BLASTP. BLASTN, and FASTA (Atschul, S F et al , J Molec Biol 215 403-410 (1990) The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S , et a . NCBI NLM NIH Bethesda, MD 20894, Altschul, S , et al , J Mol Biol 215 403-410 (1990) As an illustration, by a polynucleotide havmg a nucleotide sequence havmg at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO 1 it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence ma\ include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO 1 In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide. or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence These mutations of the reference sequence may occur at the 5 or 3 ' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence Analogously , b\ a polypeptide having an ammo acid sequence havmg at least, for example, 95% identity to a reference ammo acid sequence of SEQ ID NO 2 is intended that the ammo acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO 2 In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference ammo acid sequence, up to 5% of the ammo acid residues m the reference sequence may be deleted or substituted with another amino acid, or a number of ammo acids up to 5% of the total amino acid residues in the reference sequence ma) be inserted into the reference sequence These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups withm the reference sequence "Isolated" means altered "by the hand of man" from its natural state, i e , if it occurs in nature, it has been changed or removed from its oπgmal environment, or both For example, a polynucleotide or a polypeptide naturally present m a Irving organism is not "'isolated." but the same polynucleotide or polypeptide separated from the coexisting matenals of its natural state is "isolated", as the term is employed herem Moreover, a polynucleotide or polypeptide that is mtroduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or nonliving "Polynucleotιde(s)" generally refers to am pohnbonucleotide or polydeoxπbonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA "Polynucleotιde(s)" include, without limitation, smgle- and double-stranded DNA. DNA that is a mixture of smgle- and double- stranded regions or smgle-, double- and tnple-stranded regions, smgle- and double-stranded RNA, and RNA that is mixture of smgle- and double-stranded regions, hybnd molecules compπsmg DNA and RNA that may be single-stranded or, more typically, double-stranded, or tnple-stranded regions, or a mixture of smgle- and double-stranded regions hi addition, "polynucleotide" as used herem refers to tnple-stranded regions compnsmg RNA or DNA or both RNA .and DNA The strands in such regions may be from the same molecule or from different molecules The regions may mclude all of one or more of the molecules, but more typically mvolve only a region of some of the molecules One of the molecules of a tnple-helical region often is an ohgonucleotide As used herem, the term "polynucleotιde(s)" also mcludes DNAs or RNAs as descπbed above that contam one or more modified bases Thus. DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotιde(s)" as that term is intended herem Moreover. DNAs or RNAs compnsmg unusual bases, such as mosme, or modified bases, such as tntylated bases, to name just two examples, are polynucleotides as the tenn is used herem It will be appreciated that a great vanety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art The tenn "polynucleotιde(s)" as it is employed herem embraces such chemically, enzymatically or metabolically modified forms of polynucleotides. as well as the chemical forms of DNA and RNA charactenstic of uruses and cells, mcludmg, for example, simple and complex cells "Polynucleotιde(s)" also embraces short polynucleotides often refened to as olιgonucleotide(s) "Polypeptide(s)" refers to any peptide or protem compnsmg two or more .amino acids jomed to each other by peptide bonds or modified peptide bonds "Polypeptιde(s)" refers to both short chains, commonly refened to as peptides, oligopeptides and oligomers and to longer chams generally refened to as proteins Polypeptides may contam ammo acids other than the 20 gene encoded ammo acids "Polypeptide(s)" mclude those modified either by natural processes, such as processmg and other post-translational modifications, but also by chemical modification techniques Such modifications are well descnbed m basic texts and m more detailed monographs, as well as m a volummous research literature, and they are well known to those of skill in the art It will be appreciated that the same type of modification may be present m the same or varying degree at several sites m a given polypeptide Also, a given polypeptide may contam many types of modifications Modifications can occur anywhere m a polypeptide. mcludmg the peptide backbone, the .ammo acid side-chams, and the ammo or carboxyl termini Modifications mclude, for example, acetylation. acylation, ADP-nbosylation, amidation, covalent attachment of flavm. covalent attachment of a heme moiety . covalent attachment of a nucleotide or nucleotide denvative. covalent attachment of a lipid or lipid denvative. covalent attachment of phosphotidylmositol, cross-linking, cy chzation, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysterne. formation of pyroglutamate, formylation, gamma-carboxylation, gly cosylation. GPI anchor formation, hydroxylation, lodination, methylation. mynstoylation, oxidation, proteolytic processmg, phosphorylation. prenylation. racemization, glycosylation, lipid attachment, sulfation, gamma- carboxylation of glutamic acid residues, hydroxylation and ADP-nbosylation, selenoylation, sulfation, transfer-RNA mediated addition of ammo acids to protems. such as arginylation, and ubiquitination See, for instance. PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed , T E Creighton. W H Freeman and Company, New York (1993) and Wold, F , Posttranslational Protem Modifications Perspectives and Prospects, pgs 1-12 m POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS. B C Johnson, Ed , Academic Press. New York ( 1983), Seifter et al , Meth Enzymol 182 626-646 ( 1990) and Rattan et al , Protein Synthesis Posttranslational Modifications and Aging, Aim N Y Acad Sci 663 48- 62 (1992) Polypeptides may be branched or cyclic with or without branching Cyclic, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well "Vaπant(s) ' ' as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide Nucleotide changes may result in ammo acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below A typical variant of a polypeptide differs m ammo acid sequence from another, reference polypeptide Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and in many regions, identical A variant and reference polypeptide may differ in ammo acid sequence by one or more substitutions, additions, deletions in any combination A substituted or inserted ammo acid residue may or may not be one encoded by the genetic code A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allehc variant, or it may be a variant that is not known to occur naturally Non- naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis and by other recombinant methods known to skilled artisans EXAMPLES The examples below are earned out usmg standard techniques, which are well known and routme to those of skill m the art except where otherwise desenbed m detail The examples are illustrative, but do not limit the mvention Example 1 Strain selection, Library Production and Sequencing The polynucleotide having a DNA sequence given in Table 1 [SEQ ID NO 1 or 3] was obtained from a library of clones of chromosomal DNA of Staphylococcus aureus in E coli The sequencing data from t o or more clones containing overlapping Staphylococcus aureus DNAs was used to construct the contiguous DNA sequence in SEQ ID NO 1 Libraries may be prepared by routine methods for example, using Methods 1 and 2 below Total cellular DNA is isolated from Staphylococcus aureus WCUH 29 accordmg to standard procedures and size-fractionated by either of two methods Method 1 Total cellular DNA is mechanically sheared by passage through a needle in order to size-fractionate accordmg to standard procedures DNA fragments of up to 1 lkbp in size are rendered blunt by treatment \\ ith exonuclease and DNA polymerase. and EcoRI linkers added Fragments are hgated into the vector Lambda ZapII that has been cut with EcoRJ, the library packaged by standard procedures and E coli infected with the packaged library The library is amplified by standard procedures Method 2 Total cellular DNA is partially h drolyzed with a one or a combination of restriction enzymes appropriate to generate a series of fragments for cloning into library vectors (e g , Rsal, Pall, Alul. Bshl23 I). and such fragments are size-fractionated according to standard procedures EcoRI linkers are hgated to the DNA and the fragments then hgated into the vector Lambda ZapII that have been cut with EcoRJ. the library packaged by standard procedures, and E coli infected with the packaged library The library is amplified by standard procedures Example 2 ribB Characterization Riboflavin Biosynthesis Operon This ORF is part of an operon which encodes genes nbG. r bB, ribA and ribH Gene ribG starts at nucleotide 1 and ends at nucleotide 1029 Gene ribB starts at nucleotide 1036 and ends at nucleotide 1668 Gene r bA starts at nucleotide 1679 and ends at nucleotide 2860 Gene ribH starts at nucleotide 2873 and ends at nucleotide 3337 The operon has the following sequence [SEQ ID NO 7] ATGGATTATGCGATTCAACTTGCAAATATGGTACAAGGTCAAACAGGTGTTAATCCACCCGTTGGCGCT GTTGTAGTTAATGAAGGTAGGATTGTTGGTATTGGTGCACACTTGAGAAAAGGTGACAAGCATGCGGAG GTTCAAGCACTTGATATGGCACAACAAAATGCTGAAGGTGCGACGATTTATATTACGTTAGAGCCATGT AGTCATTTTGGTTCAACACCACCCTGTGTTAACAAAATTATTGATTGTAAGATAGCAAAAGTAGTATAC GCAACAAAAGACAATTCGTTAGACACACATGGTGATGAGACGTTACGGGCTCACGGTATTGAGGTTGAA TGCGTTGATGATGAACGGGCATCACAATTATACCAAGACTTTTTTAAAGCAAAAGCAAAGCAACTGCCA CAAATTACAGTGAAAGTATCTGCAAGTTTAGATGGTAAACAAGCGAATGATAATGGACAAAGTCAATGG ATTACTAACAAAGAGGTTAAACAAGATGTCTATAAGTTAAGACATCGACACGACGCAGTGTTAACTGGA AGACGTACAGTTGAATTAGATGATCCACAATATACTACACGTATTCAAGATGGAAAAAACCCTATAAAA GTAATATTGTCTAAGTCTGGGAATATTCATTTTAATCAGCAAATTTATCAAGATGAATCAACACCAATT TGGATATATACTGAAAATCCAAATTTAACAAGCAATCAAACACATATTGAAATTATTTACTTGAAGTCT TGTGATTTAACAACAATTCTTCACAATTTATATAAAAGAGGAGTTGGAACTTTGCTAGTCGAGGCAGGT CCAACCACTACTTCAGAATTCTCCATCTATTATATAGATGAATTTATTCTCTATTATGCCCCGAAATTA ATTGGCGGATCTGGAAATTATCAATTTTATCAAACAAATGATGTGATTGAGATACCAGATGCGAACCAA TTTGAAATTGTTCATTCCGAGTTATTAAATCAAAATGTTAAATTAACTTTACGAAAGAAGTGATGATGC ATGTTTACTGGCATCGTTGAAGAAATAGGTGTCGTTAAAAGTGTTCAAATTCGTCAATCAGTCAGGACG ATTGAAATCGAAGCACATAAGATTACGGCAGATATGCATATTGGTGATTCCATCAGTGTTAATGGTGCA TGTTTAACAGTGATTGATTTTGATCAGACATCTTTTACTGTTCAAGTAATTAAAAGCACTGAAAATAAA ACCTATTTAGCAGATGTTAAGCGACAATCAGAAGTAAATTTAGAGCGTGCCATGAGTGGTAACGGTAGG TTTGGTGGACATTTTGTCCTCGGTCATGTAGATGAACTAGGAACAGTTT CAAAAATAAATGAAACAGCCAATGCCAAAATTATTACGATTCAATGTAGCCAACATATTAATAATCAGT TAGTTAAGCAAGGGTCTATTACTGTGGATGGTGTAAGTCTAACGGTATTTGATAAGCATGATAACAGTT TTGACATTCATCTTATTCCAGAAACGAGGCGTTCAACGATTTTATCATCCAAAAAATTAGGAGATAAAG TACATTTAGAAACAGACGTTTTGTTTAAATATGTTGAAAATATTTTAAATAAAGATAAAGACCAATTAT CTGTAGATAAATTAAGAGCATTTGGTTTTTAGGAGGGGTAGCATGCAATTCGATAATATTGACAGTGCT TTAATGGCTTTAAAAAATGGAGAAACAATTATTGTAGTAGATGATGAGAATCGTGAAAATGAAGGTGAT TTAGTAGCGGTTACTGAATGGATGAACGATAATACCATTAATTTTATGGCGAAAGAAGCAAGGGGATTA ATATGCGCACCAGTGTCTAAAGATATTGCACAACGTTTGGATTTGGTACAAATGGTTGATGATAACTCC GACATCTTTGGTACGCAATTTACAGTGAGTATTGATCATGTAGATACAACAACAGGAATTAGTGCTTAT GAACGTACATTGACTGCCAAAAAGCTCATTGATCCTAGTAGTGAAGCTAAAGATTTTAATCGTCCTGGT CATTTATTTCCATTAGTAGCACAAGATAAAGGCGTATTAGCTAGAAATGGACACACAGAAGCGGCTGTT GATTTAGCTAAACTTACTGGTGCCAAGCCCGCTGGTGTCATTTGTGAGATTATGAATGATGACGGCACG ATGGCGAAAGGACAAGATTTACAAAATTTTAAAGAAAAACATCAATTAAAGATGATTACGATTGATGAT TTAATTGAATATCGTAAAAAATTAGAACCAGAAATTGAATTTAAGGCAAAAGTGAAAATGCCTACAGAT TTCGGAACATTTGATATGTATGGTTTTAAAGCGACATACACAGATGAAGAGATAGTTGTACTGACAAAA GGTGCAATTCGACAACATGAAAATGTACGCTTACATTCTGCGTGCCTTACAGGCGATATTTTCCATAGT CAACGTTGTGATTGTGGTGCTCAACTTGAATCGTCTATGAAGTATATCAATGAACATGGTGGCATGATT ATTTATCTACCTCAAGAAGGTCGTGGCATAGGATTGTTAAACAAATTACGCGCATATGAATTAATTGAG CAAGGATATGATACAGTAACTGCAAATTTAGCATTAGGTTTTGATGAAGATTTACGAGATTATCATATT GCTGCACAGATTTTAAAATATTTTAACATCGAACATATCAATTTATTAAGTAATAATCCAAGTAAATTT GAGGGATTAAAACAATATGGCATTGATATTGCAGAAAGAATTGAAGTTATCGTACCAGAAACGGTACAT AATCATGATTATATGGTAACGAAAAAAATAAAAATGGGTCATTTAATATAGGAGGACTTTAACATGAAT TTTGAAGGTAAATTAATTGGAAAAGATTTGAAAGTTGCAATCGTAGTTAGTCGATTTAATGATTTTATC ACTGGAAGATTACTTGAAGGTGCAAAAGATACTTTGATTCGACATGATGTTAATGAAGACAATATTGAT GTAGCATTTGTTCCTGGTGCGTTTGAAATTCCTTTAGTAGCTAAAAAATTAGCCTCATCAGGAAATTAT GATGCAATAATTACATTAGGATGCGTAATTCGCGGTGCTACGTCTCATTATGATTATGTTTGTAATGAA GTGCGAAAGGTGTTTCTAAAGTAAATGATCAAACTAATGTACCAGTCATATTTGGTATTTTAACGACTG AAAGTATTGAACAAGCTGTGGAAAGAGCAGGTACGAAAGCTGGTAATAAAGGTGCCGAAGCAGCAGTAA GTGCAATTGAAATGGCTAATTTATTAAAATCTATAAAAGCATAG [SEQ ID NO:7]

Claims: What is claimed is: 1 An isolated polynucleotide compπsmg a polynucleotide havmg at least a 70% identity to a polynucleotide encodmg a polypeptide compnsmg tlie ammo acid sequence of SEQ ID NO 2 2 An isolated polynucleotide compnsmg a polynucleotide havmg at least a 70% identity to a polynucleotide encodmg the same mature polypeptide expressed by the nbB gene contained m the Staphylococcus aureus of the deposited stram 3 An isolated polynucleotide compnsmg a polynucleotide encodmg a polypeptide compnsmg an ammo acid sequence which is at least 70% identical to tlie .ammo acid sequence of SEQ ID NO 2 4 An isolated polynucleotide that is complementary to tlie polynucleotide of claim 1 5 Tlie polynucleotide of Claim 1 wherem tl e polynucleotide is DNA oi RNA 6 The polynucleotide of Claim 1 compnsmg the nucleic acid sequence set forth m SEQ ID NO 1 7 The polynucleotide of Claim 1 compnsmg nucleotide 1 to the stop codon which begins at nucleotide number 631 set forth in SEQ ID NO 1 8 The polynucleotide of Claim 1 which encodes a polypeptide compnsmg tl e ammo acid sequence of SEQ ID NO 2 9 A vector compπsmg tlie polynucleotide of Claim 1 10 A host cell compπsmg the vector of Claim 9 11 A process for producmg a polypeptide compnsmg expressmg from tl e host cell of Claim 10 a polypeptide encoded by said DNA 12 A process for producmg a nbB polypeptide or fragment comprising cultuπng a host of claim 10 under conditions sufficient for the production of said polypeptide or fragment 13 A polypeptide compnsmg an amino acid sequence which is at least 70% identical to the ammo acid sequence of SEQ ID NO 2 14 A polypeptide compnsmg an am o acid sequence as set forth m SEQ ID NO 2 15 An antιbod\ agamst the polypeptide of claim 14 16 An antagonist which inhibits the activity or expression of the polypeptide of claim 14 17 A method for the treatment of an individual m need of nbB polypeptide compnsmg administering to the individual a therapeutically effective amount of the polypeptide of claim 14 18 A method for the treatment of an mdividual havmg need to mhibit nbB polypeptide compπsmg admimstenng to the mdividual a tlierapeutically effective amount of the antagonist of Claim 14 19 A process for diagnosing a disease related to expression or activity of the polypeptide of claim 14 m an mdividual compnsmg (a) deteπnining a nucleic acid sequence encodmg said polypeptide. and/or (b) analyzing for tlie presence or amount of said polypeptide m a sample denved from the mdividual 20 A method for identifying compounds winch mteract with and inhibit or activate an activity of the polypeptide of claim 14 compπsmg contacting a composition compπsmg tlie polypeptide with the compound to be screened under conditions to permit mteraction between the compound and the polypeptide to assess the mteraction of a compound, such mteraction bemg associated with a second component capable of providing a detectable signal m response to the mteraction of the polypeptide with tlie compound, .and determinmg whether the compound mteracts with and activates or inhibits an activity of the polypeptide by detectmg the presence or absence of a signal generated from the mteraction of the compound with the polypeptide 21 A method for inducing an immunological response in a mammal which comprises inoculating the mammal with nbB polypeptide of claim 14. or a fragment or variant thereof, adequate to produce antibody and/or T cell immune response to protect said animal from disease 22 A method of inducing immunological response in a mammal which comprises delivering a nucleic acid vector to direct expression of nbB polypeptide of claim 14, or fragment or a variant thereof, for expressing said nbB polypeptide, or a fragment or a variant thereof in vivo in order to induce an immunological response to produce antibody and/ or T cell immune response to protect said animal from disease 23 An isolated polynucleotide compπsmg a polynucleotide havmg at least a 70% identity to a polynucleotide encodmg a polypeptide compπsmg the amino acid sequence of SEQ ID NO 4 24 An isolated polynucleotide compπsmg a polynucleotide havmg at least a 70% identity to the polynucleotide sequence of SEQ ID NO 3

Inventors: BLACK MICHAEL T, BURNHAM MARTIN K R, FEDON JASON C, HODGSON JOHN E, KNOWLES DAVID J C, LONETTO MICHAEL A, NICHOLAS RICHARD O, PALMER LESLIE M, PRATT JULIE M, REICHARD RAYMOND W, ROSENBERG MARTIN, TRANI CHRISTOPHER M, WARD JUDITH M, WARREN RICHARD L, BLACK, MICHAEL, T., BURNHAM, MARTIN, K., R., FEDON, JASON, C., HODGSON, JOHN, E., KNOWLES, DAVID, J., C., LONETTO, MICHAEL, A., NICHOLAS, RICHARD, O., PALMER, LESLIE, M., PRATT, JULIE, M., REICHARD, RAYMOND, W., ROSENBERG, MARTIN, TRANI, CHRISTOPHER, M., WARD, JUDITH, M., WARREN, RICHARD, L.
Applicants: SMITHKLINE BEECHAM CORP, SMITHKLINE BEECHAM CORPORATION
Application year: 1998
Main classification: A61K38
IPC codes: A61K31, A61K38, A61K39, A61K48, A61P1, A61P9, A61P11, A61P13, A61P17, A61P19, A61P25, A61P27, A61P31, A61P37, A61P43, C07H21, C07K14, C07K16, C12N1, C12N5, C12N9, C12N15, C12P21, C12R1, G01N33